share_log

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares

阿克里馮治療股份有限公司（NASDAQ：ACRV）董事拉資本管理股份有限公司購入 3,389,500 股股票
Defense World ·  2022/11/22 17:21

Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at $54,802,575. The transaction was disclosed in a document filed with the SEC, which is available at this link.

阿克里馮治療有限公司（NASDAQ：ACRV-獲取評級）董事拉資本管理公司，L.P. 在 11 月 17 日（星期四）的一項交易中收購了 3,389,500 股該公司股票的股份。這些股份以每股 12.50 美元的平均價格買入，總交易額為 42,368,750.00 美元。購買後，董事現在擁有該公司 4,384,206 股股份，價值為 54,802,575 美元。該交易在向 SEC 提交的文件中披露，該文件可在以下網址獲得： 這個鏈接。

Acrivon Therapeutics Price Performance

acrivon 治療學價格表現

Shares of Acrivon Therapeutics stock opened at $12.51 on Tuesday. Acrivon Therapeutics, Inc. has a 12-month low of $12.50 and a 12-month high of $20.70.

艾克里芬治療學股票的股票在周二開盤 12.51 美元。阿克里馮治療學公司擁有 12 個月低點 12.50 美元和 12 個月高點 20.70 美元。

Get
取得
Acrivon Therapeutics
治疗学
alerts:
警報：

About Acrivon Therapeutics

關於阿克里馮治療

(Get Rating)

(取得評分)

Acrivon Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer.
Arivon 治療學公司是一家臨床階段生物製藥公司，致力於開發精準腫瘤藥物。該公司的主要臨床候選人是 ACR-368，這是一種靶向 CHK1/2 的選擇性小分子抑制劑，用於治療抗鉑性卵巢癌、子宮內膜癌和膀胱癌；以及 SCC，包括 SCCHN、宮頸癌和肛門癌。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
  • Three Ways To Win The Online Gambling Industry
  • Santa Claus Rally? Here's What Needs to Happen
  • Will the Return of Bob Iger Return the Magic to Disney Stock?
  • Is Ardelyx is A Buy After Slip in Early 2022
  • Is Tesla A Bargain Now As It Trades At Two-Year Lows?
  • 獲取有關艾克里芬治療學（ACRV）的研究報告的免費副本
  • 贏得在線賭博行業的三種方法
  • 聖誕老人拉力賽？這是需要發生的事情
  • 鮑勃·伊格爾的歸來會將魔法歸還給迪士尼股票嗎？
  • 阿德利克斯是 2022 年初滑倒後的買入嗎
  • 特斯拉現在是否討價還價，因為它交易在兩年低點？

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收有關 Arivon 治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Acrivon 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論